CXCL12 and familial pancreatic carcinoma: In view of the fact that pancreatic cancer cells are highly resistant to chemotherapy, and gemcitabine (an FDA-approved drug) is only minimally effective against this malignancy, we investigated the role of CXCL12–CXCR4 signalling axis in pancreatic cancer chemoresistance.